Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Advanced Thyroid Cancer
NCT01788982Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2014
- Primary completion
- Aug 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in differentiated thyroid cancer (DTC) and Medullary Thyroid Cancer (MTC) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Progression Free Survival at 2.5 years. Started May 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
differentiated thyroid cancer (DTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT01788982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788982.